Inozyme Pharma Long-Term Investments 2020-2024 | INZY

Inozyme Pharma long-term investments from 2020 to 2024. Long-term investments can be defined as the aggregate value of debt and or equity investments with maturities or benefits lasting more than one year.

Inozyme Pharma Long-Term Investments 2020-2024 | INZY

Inozyme Pharma long-term investments from 2020 to 2024. Long-term investments can be defined as the aggregate value of debt and or equity investments with maturities or benefits lasting more than one year.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$170.3B
Vertex Pharmaceuticals (VRTX)$122B
Bristol Myers Squibb (BMY)$112.5B
Gilead Sciences (GILD)$111.9B
Regeneron Pharmaceuticals (REGN)$91.4B
CSL (CSLLY)$90.8B
GSK (GSK)$76.6B
Argenex SE (ARGX)$35.2B
Alnylam Pharmaceuticals (ALNY)$34.8B
BioNTech SE (BNTX)$25.9B
Biogen (BIIB)$25.3B
Illumina (ILMN)$24.5B
Moderna (MRNA)$20.6B
BeiGene (BGNE)$20.2B
Genmab (GMAB)$15.1B
Incyte (INCY)$14.6B
Exact Sciences (EXAS)$13.1B
BioMarin Pharmaceutical (BMRN)$12.6B
Insmed (INSM)$12.2B
Bio-Techne Corp (TECH)$12B
Vaxcyte (PCVX)$11.9B
Sarepta Therapeutics (SRPT)$11.7B
QIAGEN (QGEN)$10B
Exelixis (EXEL)$9.8B
Bio-Rad Laboratories (BIO.B)$9.3B
Revolution Medicines (RVMD)$9.3B
Intra-Cellular Therapies (ITCI)$9.1B
Roivant Sciences (ROIV)$8.5B
Legend Biotech (LEGN)$8B
Repligen (RGEN)$7.8B